Biogen
Biogen’s natalizumab fails Phase III endpoints
October 21, 2015Biogen, multiple sclerosis
Biogen’s natalizumab has failed to achieve clinical endpoints in a late-stage study to prove the drug’s potential in patients with …
Novartis and Biogen launch drug access programmes in developing countries
October 15, 2015Manufacturing and Production, Sales and Marketing Biogen, Novartis, access, aid, corporate social responsibility, csr, humanitarian aid
Novartis and Biogen have begun new campaigns aimed at increasing access to medicines in developing countries. The Swiss firm has …
Neurimmune kicks off late-stage Alzheimer’s study
September 9, 2015Research and Development Alzheimer's disease, Biogen, Neurimmune, aducanumab, neurology
Neurimmune and its development partner Biogen are beginning a Phase III study of the companies’ potential Alzheimer’s treatment aducanumab. The …
Lilly, Biogen and Roche debut Alzheimer’s disease drug results
July 22, 2015Research and Development Alzheimer's, Alzheimer's disease, Biogen, Conference, Eli Lilly, Roche, lilly
Big pharma companies have posted mixed results in trials of several potential new treatments for Alzheimer’s disease. But the results, …
Biogen to build billion-dollar plant in Switzerland
July 7, 2015Manufacturing and Production Alzherimer's disease, Biogen, Biogen IDEC, MS, Switzerland, manufacturing, multiple sclerosis
Biogen plans to open a $1 billion manufacturing facility in Switzerland, to help Europe deal with the future demand for …
J&J and Google partner to build surgical robots
March 30, 2015Medical Communications, Sales and Marketing Biogen, Ethicon, J&J, JJ, Johnson and Johnson, MS, google, robots
The medical device subsidiary of Johnson & Johnson Ethicon is to collaborate with Google to build surgical robots and perform …
Big pharma teams with government on genomic research
March 27, 2015Research and Development, Sales and Marketing AbbVie, Alexion Pharmaceuticals, AstraZeneca, Biogen, Cameron, Dimension Therapeutics, GSK, Genomic, Genomics england, Helomics, Roche, Takeda, UCB, UK, genomes
Ten firms will partner up with Genomics England to develop new diagnostics and treatments for people with rare diseases and …
Biogen shortens name and posts positive Alzheimer’s results
March 23, 2015Sales and Marketing AD, Alzheimer's, BIIB037, Biogen, MS, Parkinson's, aducanumab, idec
Biogen Idec is to be known only as Biogen hence forth as the US biotech also reveals positive early results …
Google partners with Biogen on multiple sclerosis
January 30, 2015Medical Communications, Sales and Marketing Biogen, MS, calico, conrad, google, google x, scangos
Google is making further headway into healthcare by teaming up with Biogen Idec in order to study what leads to …
EMA review for Biogen Idec’s haemophilia A therapy
November 4, 2014Sales and Marketing Biogen, elocta, eloctate, haemophilia a, idec, sobi
The EMA is set to review Biogen Idec and Sobi’s haemophilia A therapy Elocta after validating the drug’s marketing authorisation …
NICE final ‘yes’ for Biogen’s MS pill
August 27, 2014Sales and Marketing Aubagio, Biogen, RMS, RRMS, gilenya
In final guidance published today NICE has recommended NHS funding of Biogen Idec’s new multiple sclerosis pill in patients with …
FDA approves Biogen’s long-acting MS drug
August 18, 2014Sales and Marketing Avonex, Biogen, FDA, MS, Rebif, plegridy, tecfidera
Biogen Idec has racked up another approval over the weekend after its latest multiple sclerosis treatment Plegridy gained FDA backing. …
Biogen gets CHMP thumbs up
May 27, 2014Sales and Marketing Biogen, CHMP, Gazyvaro (obinutuzumab), Nuwiq, Octapharma, Orphan, Roche, chronic lymphocytic leukaemia, plegridy
Biogen Idec is celebrating after the Committee for Medicinal Products for Human Use (CHMP) gave its multiple sclerosis drug Plegridy …
High-dose Copaxone the right medicine for Teva
January 29, 2014Research and Development, Sales and Marketing Biogen, Copaxone, FDA, MS, Mylan, Teva
The FDA has approved a high-dose version of Teva’s multiple sclerosis drug Copaxone which will help the firm offset approaching …
US nod for Tecfidera
March 28, 2013Sales and Marketing Biogen, FDA, tecfidera
The FDA has given Biogen Idec’s oral multiple sclerosis treatment Tecfidera the green light. Earlier this week Tecfidera (dimethyl fumarate) …
Latest content
AstraZeneca’s Trixeo approved in EU for asthma
ESTEVE CDMO adds $17.5m to Illinois expansion
